Hospital
Princeton Community Hospital Assn., INC.
Princeton Community Hospital Assn., INC. was paid $40.95M by Medicaid between Jan 2018 and Dec 2024, across 392 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
33Billing provider infoPRINCETON COMMUNITY HOSPITAL ASSN., INC.
PRINCETON, WV 24740
PRINCETON, WV 24740
33aNPI1558313213assigned 05/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$40.95M
24GClaims1,209,072
24DCodes billed392
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#8 of 26
Median peer was paid$18.33M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 155,894 | $7.97M | |
| 2019 | 108,079 | $4.83M | |
| 2020 | 180,862 | $6.95M | |
| 2021 | 206,524 | $5.12M | |
| 2022 | 175,576 | $5.75M | |
| 2023 | 211,926 | $5.53M | |
| 2024incomplete | 170,211 | $4.79M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 23,276 | 19,887 | $7.83M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 35,529 | 31,183 | $5.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 42,545 | 37,770 | $4.19M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.3% | 10,088 | 8,483 | $958K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 12,475 | 9,439 | $845K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 88,102 | 68,727 | $762K |
| 80053 | Comprehensive metabolic panel | 1.6% | 69,786 | 55,369 | $663K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 11,807 | 8,282 | $595K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 4,971 | 4,460 | $488K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 7,225 | 6,534 | $481K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 11,344 | 3,066 | $471K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 9,452 | 8,057 | $467K |
380 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 7,365 | $459K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 8,300 | $443K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 3,091 | $443K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 24,618 | $423K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,514 | $402K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17,515 | $394K |
| 36415 | Collection of venous blood by venipuncture | <1% | 64,042 | $381K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,087 | $381K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,479 | $360K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,498 | $359K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,858 | $354K |
| G0378 | Hospital observation service, per hour | <1% | 5,025 | $328K |
| 81001 | <1% | 39,303 | $291K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,051 | $275K |
| 84484 | <1% | 22,011 | $273K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,647 | $250K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,381 | $245K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,908 | $219K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 27,008 | $216K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12,752 | $215K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,791 | $212K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,979 | $208K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,692 | $197K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,586 | $193K |
| 87070 | <1% | 12,607 | $190K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,751 | $189K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,778 | $184K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 716 | $172K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,692 | $168K |
| 83605 | <1% | 16,428 | $165K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,980 | $160K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,000 | $159K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,140 | $154K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,266 | $153K |
| 86140 | <1% | 15,126 | $153K | |
| 93017 | <1% | 1,593 | $149K | |
| 87040 | <1% | 11,807 | $145K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,089 | $144K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,189 | $143K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,408 | $139K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,598 | $139K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,967 | $131K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 938 | $128K |
| 72110 | <1% | 3,823 | $127K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,340 | $126K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,847 | $125K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,700 | $123K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,411 | $123K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,475 | $121K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 312 | $118K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,331 | $117K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,964 | $117K |
| 96376 | <1% | 4,484 | $112K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,766 | $111K |
| 85027 | <1% | 10,962 | $109K | |
| 74178 | <1% | 847 | $109K | |
| 59025 | Fetal non-stress test | <1% | 2,353 | $108K |
| 82805 | <1% | 2,757 | $107K | |
| 81025 | <1% | 5,154 | $106K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,816 | $106K |
| 83690 | <1% | 10,156 | $98K | |
| 80061 | Lipid panel | <1% | 7,667 | $91K |
| 88304 | <1% | 1,360 | $91K | |
| 73630 | <1% | 2,475 | $86K | |
| 82962 | <1% | 8,345 | $86K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 782 | $85K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,116 | $80K |
| 74019 | <1% | 3,789 | $79K | |
| 80076 | <1% | 5,241 | $78K | |
| 87631 | <1% | 728 | $77K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,968 | $75K |
| 80047 | <1% | 3,654 | $74K | |
| 82150 | <1% | 4,520 | $73K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 487 | $72K |
| 82607 | <1% | 5,446 | $70K | |
| 36600 | <1% | 3,302 | $69K | |
| 93971 | <1% | 1,426 | $68K | |
| 49083 | <1% | 271 | $67K | |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 513 | $64K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 56 | $64K |
| 83735 | <1% | 13,309 | $64K | |
| 78227 | <1% | 237 | $63K | |
| 73030 | <1% | 2,926 | $60K | |
| 73562 | <1% | 2,545 | $60K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 384 | $60K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,957 | $60K |
| 83880 | <1% | 3,556 | $59K | |
| 88342 | <1% | 1,210 | $58K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,165 | $56K |
| 86885 | <1% | 2,037 | $55K | |
| 97161 | <1% | 1,269 | $54K | |
| 47563 | <1% | 79 | $54K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,097 | $53K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,681 | $52K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,956 | $52K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,289 | $52K |
| 72050 | <1% | 1,275 | $52K | |
| 96367 | <1% | 3,165 | $51K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 98 | $51K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 5,555 | $51K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,640 | $50K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,019 | $50K |
| 86900 | <1% | 3,177 | $50K | |
| 85610 | <1% | 11,149 | $50K | |
| 80050 | General health panel | <1% | 1,279 | $49K |
| 85730 | <1% | 8,643 | $48K | |
| 90715 | <1% | 1,353 | $48K | |
| 73130 | <1% | 1,916 | $47K | |
| 70486 | <1% | 793 | $46K | |
| 73610 | <1% | 2,040 | $46K | |
| 82550 | <1% | 4,907 | $45K | |
| 87077 | <1% | 5,122 | $44K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,201 | $43K |
| 87186 | <1% | 5,042 | $43K | |
| 76536 | <1% | 672 | $42K | |
| 84703 | <1% | 4,065 | $41K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,198 | $39K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 69 | $38K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,509 | $38K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,707 | $37K |
| 73502 | <1% | 1,883 | $33K | |
| 73110 | <1% | 1,192 | $33K | |
| 85007 | <1% | 4,286 | $33K | |
| 82553 | <1% | 2,203 | $33K | |
| 82565 | <1% | 2,866 | $33K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,959 | $32K |
| 82746 | <1% | 2,472 | $32K | |
| 72070 | <1% | 1,028 | $32K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 993 | $31K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 994 | $31K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,408 | $29K |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | <1% | 1,037 | $29K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 599 | $29K |
| 71250 | <1% | 906 | $28K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 83 | $27K |
| 86901 | <1% | 3,177 | $27K | |
| 74018 | <1% | 1,329 | $27K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,984 | $27K |
| 72141 | <1% | 122 | $26K | |
| 97162 | <1% | 416 | $26K | |
| 76830 | Ultrasound, transvaginal | <1% | 339 | $25K |
| 87081 | <1% | 5,257 | $25K | |
| 82140 | <1% | 2,297 | $25K | |
| 84702 | <1% | 1,628 | $23K | |
| 85379 | <1% | 2,816 | $22K | |
| 96415 | <1% | 733 | $22K | |
| 73564 | <1% | 899 | $22K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,844 | $21K |
| 84466 | <1% | 1,916 | $21K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 337 | $20K |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 240 | $20K |
| 88307 | <1% | 216 | $20K | |
| 87075 | <1% | 1,108 | $19K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 601 | $19K |
| 82728 | <1% | 2,027 | $18K | |
| 84520 | <1% | 672 | $18K | |
| 83540 | <1% | 2,897 | $17K | |
| 73080 | <1% | 667 | $16K | |
| 76775 | <1% | 338 | $16K | |
| 73590 | <1% | 404 | $15K | |
| 80143 | <1% | 1,812 | $15K | |
| 97035 | <1% | 390 | $14K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,374 | $14K |
| 73221 | <1% | 61 | $14K | |
| 76770 | <1% | 355 | $13K | |
| 84439 | <1% | 1,597 | $13K | |
| 86308 | <1% | 370 | $13K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 143 | $13K |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 154 | $12K |
| 36430 | <1% | 204 | $12K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,798 | $12K |
| 87632 | <1% | 48 | $12K | |
| 86038 | <1% | 630 | $11K | |
| 76642 | <1% | 294 | $11K | |
| 82247 | <1% | 2,055 | $11K | |
| 97014 | <1% | 348 | $11K | |
| 85652 | <1% | 1,517 | $11K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 918 | $10K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,294 | $10K |
| 83970 | <1% | 461 | $10K | |
| 84436 | <1% | 1,180 | $10K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 173 | $10K |
| 93880 | <1% | 107 | $9K | |
| 93975 | <1% | 93 | $9K | |
| 71100 | <1% | 387 | $9K | |
| 12001 | <1% | 72 | $9K | |
| 80179 | <1% | 1,093 | $9K | |
| 72100 | <1% | 493 | $9K | |
| 87150 | <1% | 306 | $8K | |
| 82542 | <1% | 119 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 219 | $8K |
| 88104 | <1% | 238 | $8K | |
| 58661 | <1% | 17 | $8K | |
| 30802 | <1% | 13 | $8K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,722 | $7K |
| 82248 | <1% | 1,900 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 180 | $7K |
| 87420 | <1% | 208 | $7K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 48 | $7K |
| 83655 | <1% | 529 | $7K | |
| 96368 | <1% | 830 | $6K | |
| 84112 | <1% | 68 | $6K | |
| 80074 | <1% | 180 | $6K | |
| 84550 | <1% | 1,592 | $6K | |
| 85018 | <1% | 674 | $6K | |
| 80305 | <1% | 1,046 | $6K | |
| 74300 | <1% | 65 | $6K | |
| 85014 | <1% | 540 | $6K | |
| 82784 | <1% | 273 | $5K | |
| 82803 | <1% | 988 | $5K | |
| 87653 | <1% | 189 | $5K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 108 | $5K |
| 90686 | <1% | 547 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 304 | $5K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,534 | $5K |
| 84479 | <1% | 611 | $5K | |
| 82043 | <1% | 1,234 | $5K | |
| A4649 | Surgical supply; miscellaneous | <1% | 75 | $5K |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 98 | $4K |
| 86430 | <1% | 237 | $4K | |
| 73090 | <1% | 265 | $4K | |
| 82105 | <1% | 338 | $4K | |
| 77066 | Tomosynthesis, mammo | <1% | 89 | $4K |
| J3490 | Unclassified drugs | <1% | 7,568 | $4K |
| 76870 | <1% | 67 | $4K | |
| 10060 | <1% | 67 | $4K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 12 | $4K |
| 31231 | <1% | 57 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 94 | $4K |
| 87506 | <1% | 33 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,062 | $3K |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 207 | $3K |
| 93226 | <1% | 104 | $3K | |
| 83550 | <1% | 851 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,803 | $3K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 131 | $3K |
| 86780 | <1% | 307 | $3K | |
| 82570 | <1% | 1,050 | $3K | |
| 82950 | <1% | 733 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 84 | $3K |
| 93225 | <1% | 104 | $3K | |
| 81003 | <1% | 3,029 | $3K | |
| 83630 | <1% | 65 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 467 | $3K |
| 97116 | <1% | 259 | $3K | |
| 93970 | <1% | 43 | $3K | |
| 86592 | <1% | 604 | $3K | |
| 36591 | <1% | 47 | $3K | |
| 82009 | <1% | 35 | $3K | |
| 87634 | <1% | 58 | $3K | |
| 84100 | <1% | 753 | $2K | |
| 70491 | <1% | 43 | $2K | |
| 94664 | <1% | 97 | $2K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 167 | $2K |
| 86850 | <1% | 679 | $2K | |
| 95117 | <1% | 253 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 78 | $2K |
| 77080 | <1% | 50 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,212 | $2K |
| 86738 | <1% | 92 | $2K | |
| 31575 | <1% | 48 | $2K | |
| 80069 | <1% | 303 | $2K | |
| 84153 | <1% | 132 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 58 | $2K |
| 87493 | <1% | 26 | $2K | |
| 86618 | <1% | 74 | $2K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 34 | $2K |
| 70492 | <1% | 27 | $2K | |
| 83721 | <1% | 212 | $2K | |
| 86300 | <1% | 155 | $2K | |
| 51702 | <1% | 410 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 218 | $1K |
| 73140 | <1% | 91 | $1K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 16 | $1K |
| 84165 | <1% | 63 | $1K | |
| 86803 | <1% | 127 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 78 | $1K |
| 87205 | <1% | 605 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 834 | $1K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 65 | $1K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 124 | $1K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,060 | $1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 34 | $1K |
| J1815 | Injection, insulin, per 5 units | <1% | 503 | $1K |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 97 | $1K |
| 87340 | <1% | 69 | $1K | |
| 86706 | <1% | 48 | $1K | |
| 92567 | <1% | 180 | $953.01 | |
| C1769 | Guide wire | <1% | 225 | $949.76 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 449 | $869.78 |
| 83615 | <1% | 214 | $848.76 | |
| 86705 | <1% | 32 | $762.53 | |
| 97164 | <1% | 14 | $759.55 | |
| 86704 | <1% | 31 | $668.51 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 523 | $617.63 |
| 86707 | <1% | 28 | $615.95 | |
| 87350 | <1% | 28 | $615.34 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 29 | $598.68 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,014 | $548.64 |
| 87521 | Neg quan hep c or qual rna | <1% | 18 | $540.64 |
| 82272 | <1% | 222 | $532.98 | |
| 87147 | <1% | 226 | $519.54 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $487.86 |
| 83021 | <1% | 33 | $445.28 | |
| 73552 | <1% | 41 | $431.40 | |
| 72131 | <1% | 16 | $421.30 | |
| 87210 | <1% | 91 | $417.26 | |
| 73522 | <1% | 43 | $416.60 | |
| 99152 | <1% | 140 | $413.44 | |
| 87076 | <1% | 40 | $412.78 | |
| 86431 | <1% | 93 | $410.77 | |
| 84156 | <1% | 291 | $372.43 | |
| 92610 | <1% | 14 | $358.24 | |
| 80055 | <1% | 15 | $357.50 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $357.19 |
| 82378 | <1% | 53 | $350.19 | |
| 73560 | <1% | 27 | $328.77 | |
| 83498 | <1% | 15 | $308.29 | |
| 80164 | <1% | 39 | $300.49 | |
| 88302 | <1% | 17 | $285.67 | |
| 80051 | <1% | 53 | $278.43 | |
| 84132 | <1% | 31 | $265.84 | |
| 86703 | <1% | 32 | $249.44 | |
| 83789 | <1% | 15 | $233.92 | |
| 84460 | <1% | 129 | $231.94 | |
| 84144 | <1% | 14 | $218.29 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 571 | $214.56 |
| 86769 | <1% | 14 | $201.27 | |
| 84450 | <1% | 112 | $193.86 | |
| 83520 | <1% | 16 | $190.04 | |
| 82010 | <1% | 39 | $187.92 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 38 | $176.97 |
| 82139 | <1% | 16 | $171.45 | |
| 82077 | <1% | 1,714 | $163.16 | |
| 86920 | <1% | 16 | $162.16 | |
| 82261 | <1% | 15 | $156.27 | |
| 82016 | <1% | 15 | $153.21 | |
| 82128 | <1% | 15 | $131.77 | |
| 86923 | <1% | 37 | $126.67 | |
| 83020 | <1% | 15 | $123.59 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 47 | $122.23 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 33 | $116.05 |
| 82040 | <1% | 25 | $115.06 | |
| 82776 | <1% | 15 | $114.42 | |
| 73060 | <1% | 13 | $105.74 | |
| 84510 | <1% | 15 | $105.34 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 97 | $96.08 |
| 74022 | <1% | 13 | $92.65 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,460 | $79.59 |
| 84437 | <1% | 15 | $77.64 | |
| 72170 | <1% | 13 | $67.17 | |
| 82270 | <1% | 55 | $65.71 | |
| 84030 | <1% | 15 | $61.42 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 57 | $46.30 |
| 84155 | <1% | 12 | $40.23 | |
| 51798 | <1% | 12 | $36.62 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 17 | $33.52 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 131 | $33.36 |
| 96523 | <1% | 30 | $25.72 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 14 | $25.00 |
| 84075 | <1% | 39 | $24.81 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 89 | $23.62 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 22 | $12.56 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 15 | $11.76 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 14 | $10.70 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | <1% | 14 | $9.08 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 262 | $2.44 |
| A4648 | Tissue marker, implantable, any type, each | <1% | 13 | $1.07 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 76 | $0.98 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 828 | $0.65 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 40 | $0.43 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 17 | $0.36 |
| A9270 | Non-covered item or service | <1% | 103 | $0.14 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 106 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 89 | $0.00 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 59 | $0.00 |
| 77062 | 0% | 25 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 31 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSPENCER, DIANE (VP OF FINANCE/CFO)
| Provider | Location | Paid |
|---|---|---|
| Princeton Community Hospital Assn INC. | Princeton, WV | $15.37M |
| Princeton Community Hospital Assn., INC | Bluefield, VA | $413K |
| Princeton Community Hospital Assn., INC | Bluefield, WV | $397K |
| Princeton Community Hospital Assn., INC | Bluefield, WV | $301K |
| Princeton Community Hospital Assn., INC | Bluefield, VA | $184K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.